Evidence map›Paper›PMID 28839167›Full record

ArticleScientific reports2017

Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.

Shieh-Yueh Yang, Ming-Jang Chiu, Ta-Fu Chen, Chin-Hsien Lin, Jiann-Shing Jeng, Sung-Chun Tang, Yen-Fu Lee, Che-Chuan Yang, Bing-Hsien Liu, Hsin-Hsien Chen and 1 more

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Tau: a biomarker of Huntington's disease.Molecular psychiatry · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shieh-Yueh YangMagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan. syyang@magqu.com.
Ming-Jang ChiuDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Ta-Fu ChenDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Chin-Hsien LinDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Jiann-Shing JengDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Sung-Chun TangDepartment of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Yen-Fu LeeMagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.
Che-Chuan YangMagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.
Bing-Hsien LiuMagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.
Hsin-Hsien ChenMagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.
Chau-Chung WuDepartments of Internal Medicine and Primary Care Medicine, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.

Indexed as

AgedAged, 80 and overDiagnostic Tests, RoutineFeasibility StudiesHumansMass ScreeningMiddle AgedNeurodegenerative DiseasesPlasmaROC CurveSensitivity and Specificitytau Proteinstau Proteins

Identifiers

PMID28839167
PMCPMC5571227
OpenAlexW2747739653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.